Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults
with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.